

Paris, March 14, 2019

SEPPIC launches SIMULGEL™ EG QD for Japanese market

SEPPIC launches SIMULGEL™ EG QD⁽¹⁾, a thickening-stabilizing-texturizing polymer proved as Quasi-Drug (QD) additive in Japan.

SEPPIC has developed the QD analytical methods in order to prove the conformity of SIMULGEL™ EG QD according to the QD monograph. A Certificate of Analysis conforming to the QD monograph is now provided with this product.

SIMULGEL™ EG QD is a liquid and multifunctional rheological modifier. It provides excellent thickening, stabilizing and texturizing properties. Compatible with most of ingredients used in topic formulation, it is suitable for products considered as Quasi-Drug categories in Japan, such as deodorants, whitening, anti-aging, oily skin or acne treatment etc.

Juanshu SHEN, product manager, stated: *“SIMULGEL™ EG QD meets QD regulatory requirements in Japan and the local needs of our customers. This also shows our analytical expertise applied to polymers.”*

- (1) INCI name: Sodium Acrylate/Sodium Acryloyldimethyl Taurate Copolymer and Isohexadecane and Polysorbate 80;
QD additive name: Sodium Acrylate · Sodium Acryloyldimethyltaurate Copolymer / Isohexadecane / Polysorbate 80

SEPPIC in brief

A subsidiary of the Air Liquide group in the Healthcare business, Seppic creates and markets a wide range of **specialty ingredients for health and beauty**. Present in **100 countries** through its subsidiaries and its network of distributors, Seppic employs **700 people** worldwide, including **100 employees dedicated to innovation**. www.seppic.com

Air Liquide Healthcare

Supplies **medical gases, home healthcare services, hygiene products, medical equipment and specialty ingredients**. In 2018, it served over **15,000 hospitals and clinics** and more than **1.6 million patients** at home throughout the world. The Group's Healthcare business reached **€3,5 billion in revenues in 2018**, with the support of its **16,500 employees**.



CONTACTS

Communication SEPPIC

Alexandra Gilbert
+33 (0)1 42 91 41 18

FP2COM pour SEPPIC

Florence Portejoie
+ 33 (0) 6 07 76 82 83

The world leader in gases, technologies and services for Industry and Health, Air Liquide is present in 80 countries with approximately 65,000 employees and serves more than 3.5 million customers and patients. Oxygen, nitrogen and hydrogen are essential small molecules for life, matter and energy. They embody Air Liquide's scientific territory and have been at the core of the company's activities since its creation in 1902.

Air Liquide's ambition is to lead its industry, deliver long term performance and contribute to sustainability. The company's customer-centric transformation strategy aims at profitable growth over the long term. It relies on operational excellence, selective investments, open innovation and a network organization implemented by the Group worldwide. Through the commitment and inventiveness of its people, Air Liquide leverages energy and environment transition, changes in healthcare and digitization, and delivers greater value to all its stakeholders.

Air Liquide's revenue amounted to 21 billion euros in 2018 and its solutions that protect life and the environment represented more than 40% of sales. Air Liquide is listed on the Euronext Paris stock exchange (compartment A) and belongs to the CAC 40, EURO STOXX 50 and FTSE4Good indexes.